Robert E. Claypoole Sells 28,786 Shares of Bioventus Inc. (NYSE:BVS) Stock

Bioventus Inc. (NYSE:BVS - Get Free Report) CEO Robert E. Claypoole sold 28,786 shares of the business's stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $9.10, for a total transaction of $261,952.60. Following the sale, the chief executive officer now owns 64,964 shares in the company, valued at $591,172.40. This represents a 30.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Bioventus Stock Down 3.2 %

Bioventus stock traded down $0.29 during trading hours on Tuesday, hitting $8.87. The company had a trading volume of 304,386 shares, compared to its average volume of 351,934. The firm has a market capitalization of $719.84 million, a P/E ratio of -14.54 and a beta of 0.85. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The firm's fifty day moving average is $11.08 and its 200-day moving average is $10.17. Bioventus Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.38.

Bioventus (NYSE:BVS - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The company reported $0.06 earnings per share for the quarter, meeting the consensus estimate of $0.06. The firm had revenue of $138.96 million for the quarter, compared to analyst estimates of $132.57 million. Bioventus had a negative net margin of 7.11% and a positive return on equity of 15.61%. During the same quarter in the prior year, the business earned $0.05 EPS. On average, research analysts forecast that Bioventus Inc. will post 0.41 earnings per share for the current year.

Analyst Ratings Changes

BVS has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. upgraded shares of Bioventus from an "underweight" rating to a "neutral" rating and boosted their price target for the company from $12.00 to $13.00 in a report on Tuesday, December 17th. Craig Hallum boosted their price target on shares of Bioventus from $12.00 to $17.00 and gave the company a "buy" rating in a report on Friday, September 27th. Finally, Canaccord Genuity Group boosted their price target on shares of Bioventus from $12.00 to $15.00 and gave the company a "buy" rating in a report on Wednesday, November 6th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of BVS. Virtus Fund Advisers LLC acquired a new position in shares of Bioventus during the 3rd quarter worth $42,000. Quest Partners LLC acquired a new position in shares of Bioventus during the 3rd quarter worth $51,000. Quarry LP acquired a new position in shares of Bioventus during the 3rd quarter worth $59,000. Covestor Ltd bought a new stake in shares of Bioventus during the 3rd quarter worth $69,000. Finally, Mackenzie Financial Corp bought a new stake in shares of Bioventus during the 2nd quarter worth $77,000. Institutional investors and hedge funds own 62.94% of the company's stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.